Abstract
Prostate cancer is one of the most common malignant neoplasms in men worldwide, and is the fifth cause of cancer-related death. In recent years, a new generation of therapies have been approved for the management of metastatic disease. Moreover, the development of new immunotherapeutic drugs has become a novel frontier for the treatment of several tumor types; to date, numerous studies have investigated their potential activity, including in prostate cancer. In this article, we discuss the role of emerging immunotherapeutic drugs in prostate cancer patients.
Original language | English |
---|---|
Article number | 2627 |
Journal | International Journal of Molecular Sciences |
Volume | 18 |
Issue number | 12 |
DOIs | |
Publication status | Published - Dec 5 2017 |
Keywords
- Antibodies
- CTLA4
- Immunotherapy
- PD-L1
- PD1
- Prostate cancer
- Vaccines
ASJC Scopus subject areas
- Catalysis
- Molecular Biology
- Spectroscopy
- Computer Science Applications
- Physical and Theoretical Chemistry
- Organic Chemistry
- Inorganic Chemistry